Showing 8 of 1220 articles
-
We discuss the benefits and tax implications behind intercompany royalty payments as a profit repatriation strategy for MNCs in China.
-
We analyze why transitioning to a digital expense management system can be cost effective for your business in China and assess the best options available.
-
Effective April 2021, the new VAT policy will benefit five more sectors, including pharmaceuticals.
-
We discuss company best practices for utilizing China’s export tax rebates and assess the risks associated with the frequent compliance and rule changes.
-
A case study analysing the new “same jurisdiction/same treaty benefit rule” when applying DTA benefits to avail lower tax rates for dividend repatriation.
-
China’s tax body has clarified a preferential corporate income tax (CIT) policy for small and low-profit enterprises and individual businesses, in place till December 31, 2022.
-
China has increased the ratio of additional deduction on manufacturing firms’ R&D expenses from 75 percent to 100 percent.
-
China has extended a package of expired or to-be-expired preferential tax and fee policies as well as rolled out new structural tax and fee cut measures.
Showing 8 of 1220 articles